First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel

ObjectiveCutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer worldwide. It is usually treated surgically, with very high cure rates. However, in 3%-7% of cases, cSCC metastasizes to lymph nodes or distant organs. Many of the affected patients are elderly with...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Itamar Averbuch, Saeed Salman, Noa Shtamper, Ilana Doweck, Aron Popovtzer, Gal Markel, Daniel Hendler, Inbar Finkel, Assaf Moore, Eyal Fenig, Tarek Taha, Kamel Mhameed, Noga Kurman, Salem Billan
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2023-01-01
Σειρά:	Frontiers in Oncology
Θέματα:	PD-1 inhibitor cemiplimab pembrolizumab radiotherapy cutaneous squamous cell carcinoma (cSCC) real-world experience
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1117804/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!